详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

mRNA Vaccine-A New Cancer Treatment Strategy

120| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute Sichuan Cancer Center School of Medicine University of Electronic Science and Technology of China, Chengdu, Sichuan 610047, China. [2]Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People\'s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China. [3]School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, China. [4]Biotherapy Center, Third Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, China. [5]UIntegrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute Sichuan Cancer Center School of Medicine University of Electronic Science and Technology of China, Chengdu, Sichuan 610047, China.

出处：

DOI：

ISSN：

摘要：

The corresponding mRNA vaccines Comirnaty (BNT162b2) and Spikevax (mRNA-1273) have been authorized for emergency use since the COVID-19 outbreak. Most clinical researches have also discovered that the mRNA vaccine is a revolutionary strategy for preventing and treating numerous diseases, including cancers. Unlike viral vectors or DNA vaccines, mRNA vaccines cause the body to directly produce proteins following injection. Delivery vectors and mRNAs that encode tumor antigens or immunomodulatory molecules work together to trigger an anti-tumor response. Before mRNA vaccines may be employed in clinical trials, a number of challenges need to be resolved. These include establishing effective and safe delivery systems, generating successful mRNA vaccines against diverse types of cancers, and proposing improved combination therapy. Therefore, we need to improve vaccine-specific recognition and develop mRNA delivery mechanisms. This review summarizes the complete mRNA vaccines' elemental composition and discusses recent research progress and future direction for mRNA tumor vaccines.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2023]版：

Q3 ONCOLOGY

最新[2023]版：

Q3 ONCOLOGY

影响因子： 2.3 最新[2023版] 3.1 最新五年平均 2.3 出版当年[2023版] 3.1 出版当年五年平均 3 出版前一年[2022版]

第一作者：

第一作者机构： [1]Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute Sichuan Cancer Center School of Medicine University of Electronic Science and Technology of China, Chengdu, Sichuan 610047, China. [2]Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People\'s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.

通讯作者：

通讯机构： [1]Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute Sichuan Cancer Center School of Medicine University of Electronic Science and Technology of China, Chengdu, Sichuan 610047, China. [2]Department of Oncology, Sichuan Academy of Medical Sciences, Sichuan Provincial People\'s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 610072, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：